Laurus Labs Limited (NSEI: LAURUSLABS)
Health Care · Pharmaceuticals · IN
Rs2,036.60
+2.65% today · +132.3% 1Y
Laurus Labs Limited (NSEI: LAURUSLABS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $11.37B and employs 7,059 people.
Over the last twelve months the share price has gained 132.3%, trading between 843.00 and 2.06K.
Tweenvest scores Laurus Labs Limited across four factors: quality 69/100, value 7/100, growth 66/100, dividend 67/100. Its strongest factor is quality.
LAURUSLABS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.37B
- Revenue (TTM)
- $768.85M
- P/E
- 100.68
- EPS
- 20.23
- Dividend yield
- 0.12%
- Beta (5Y)
- 0.34
- 52-week high
- Rs2,055.30
- 52-week low
- Rs843.00
- Avg volume (3M)
- —
- Shares outstanding
- 540.31M
- Employees
- 7,059
- Next earnings
- —
About Laurus Labs Limited
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
- ISIN
- INE947Q01028
- Founded
- 2005
- Listed since
- Dec 19, 2016
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sino Biopharmaceutical LimitedSEHK: 1177 | $12.28B | HK$5.41 | -1.37% |
| Recordati Industria Chimica e Farmaceutica S.p.A.BIT: REC | $12.15B | €52.95 | -0.09% |
| Zydus Lifesciences LimitedNSEI: ZYDUSLIFE | $11.52B | Rs1,117.50 | -2.46% |
| Elanco Animal Health IncorporatedNYSE: ELAN | $11.45B | $22.78 | -0.61% |
| Cipla LimitedNSEI: CIPLA | $10.86B | Rs1,301.00 | -3.20% |
| Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.SHSE: 600436 | $10.79B | CN¥119.82 | +1.38% |
| Dr. Reddy's Laboratories LimitedBSE: 500124 | $10.29B | Rs1,195.10 | +1.28% |
| Mankind Pharma LimitedNSEI: MANKIND | $10.11B | Rs2,368.50 | -6.57% |
Figures last refreshed Oct 11, 2026.